Blood
Articles in this Issue
How to prioritize between oxygen and iron
Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma
Abstract Soluble B-cell maturation antigen (sBCMA) is elevated on multiple myeloma (MM) cells. We investigated whether sBCMA levels correlated with other myeloma tumor volume indicat...
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Abstract The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic frailty assessment improved...
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia
Abstract Glutamine dependency has been shown to be a metabolic vulnerability in acute myeloid leukemia (AML). Prior studies using several in vivo AML models showed that depletion of...
Woyach JA, Burbano GP, Ruppert AS, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. <i>Blood</i>. 2024;143(16):1616-1627.
A bulge uridine in the HIF2α IRE allows IRP1 but not IRP2 to selectively regulate HIF2α expression and ensuing EPO levels
Abstract Iron regulatory proteins (IRP1 and IRP2) play a pivotal role in maintaining cellular iron homeostasis by binding to iron-responsive elements (IREs) of target messenger RNAs...
Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management
Abstract Sterile alpha motif domain–containing protein 9 (SAMD9) and SAMD9-like (SAMD9L) are paralogous genes encoding antiviral proteins that negatively regulate cell proliferation....
For how long has this problem been there?
c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with <i>NPM1</i> mutation
Quantifying MM disease burden by BCMA?
Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia
Abstract CD47 is overexpressed on the surface of many types of cancer cells, including T-cell acute lymphoblastic leukemia (T-ALL) cells. In this study, we have developed a diphtheri...
A novel therapy with a rational design for AML
Xu H, Cao Y, Yang X, Cai P, Kang L, Zhu X, Luo H, Lu L, Wei L, Bai X, Zhu Y, Zhao B-Q, Fan W. ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery. <i>Blood</i>. 2017;130(1):11-22.
This article has been retracted; please see Elsevier’s Article Correction, Retraction and Removal Policy (Article withdrawal | Elsevier policy). This article has been retracted at th...
Development of hyperdiploidy starts at an early age and takes a decade to complete
Abstract Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy...
Targeting CD47: many misses; hopeful for a hit
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation
Abstract TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib,...
A 3-pronged attack on <i>TP53</i>-mutated MCL
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS
Abstract Anemia is the most prevalent cytopenia in lower-risk myelodysplastic neoplasms (LR-MDS). There is a paucity of drugs for red blood cell transfusion dependence (RBC-TD), and...